Why the study?
Aldosterone receptor blockers reduce cardiac-related events, but their efficacy in hemodialysis patients was unclear.
Does spironolactone 25 mg/day reduce cardiovascular and cerebrovascular events in oligoanuric hemodialysis patients?
Population
309 oligoanuric HD patients across 5 clinics
Comparison
Spironolactone 25 mg/day vs control
Design
Multicenter randomized trial
Follow-up
3 years
Authors
Loading...
Hypothesis-generating for spironolactone in HD to reduce CCV events; larger RCTs needed before clinical adoption.**[[1]](https://www.jacc.org/doi/10.1016/j.jacc.2013.09.056)[[1]](https://www.jacc.org/doi/10.1016/j.jacc.2013.09.
Does spironolactone 25 mg/day reduce cardiovascular and cerebrovascular events in oligoanuric hemodialysis patients?
Spironolactone 25 mg/day significantly reduces cardiovascular and cerebrovascular morbidity and all-cause mortality in oligoanuric hemodialysis patients, with an acceptable safety profile.
Matsumoto et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: